TVGN vs. ALGS, INAB, OKYO, BCLI, ACHL, QNCX, ESLA, NKGN, SRZN, and INKT
Should you be buying Tevogen Bio stock or one of its competitors? The main competitors of Tevogen Bio include Aligos Therapeutics (ALGS), IN8bio (INAB), OKYO Pharma (OKYO), Brainstorm Cell Therapeutics (BCLI), Achilles Therapeutics (ACHL), Quince Therapeutics (QNCX), Estrella Immunopharma (ESLA), NKGen Biotech (NKGN), Surrozen (SRZN), and MiNK Therapeutics (INKT). These companies are all part of the "biological products, except diagnostic" industry.
Tevogen Bio (NASDAQ:TVGN) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, community ranking, profitability and risk.
Aligos Therapeutics received 23 more outperform votes than Tevogen Bio when rated by MarketBeat users.
Tevogen Bio has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -783.72%. Tevogen Bio's return on equity of -21.83% beat Aligos Therapeutics' return on equity.
Tevogen Bio has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.37, meaning that its stock price is 137% more volatile than the S&P 500.
In the previous week, Aligos Therapeutics had 1 more articles in the media than Tevogen Bio. MarketBeat recorded 3 mentions for Aligos Therapeutics and 2 mentions for Tevogen Bio. Tevogen Bio's average media sentiment score of 1.87 beat Aligos Therapeutics' score of 0.94 indicating that Tevogen Bio is being referred to more favorably in the media.
60.4% of Aligos Therapeutics shares are held by institutional investors. 56.6% of Tevogen Bio shares are held by company insiders. Comparatively, 16.5% of Aligos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Tevogen Bio has higher earnings, but lower revenue than Aligos Therapeutics.
Summary
Tevogen Bio beats Aligos Therapeutics on 6 of the 11 factors compared between the two stocks.
Get Tevogen Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tevogen Bio Competitors List
Related Companies and Tools
